RS59435B1 - Nova jedinjenja sulfonimidoil purinona i njihovi derivati za lečenje i profilaksu virusne infekcije - Google Patents

Nova jedinjenja sulfonimidoil purinona i njihovi derivati za lečenje i profilaksu virusne infekcije

Info

Publication number
RS59435B1
RS59435B1 RSP20191351A RS59435B1 RS 59435 B1 RS59435 B1 RS 59435B1 RS P20191351 A RSP20191351 A RS P20191351A RS 59435 B1 RS59435 B1 RS 59435B1
Authority
RS
Serbia
Prior art keywords
purin
methyl
amino
compound
oxo
Prior art date
Application number
Other languages
English (en)
Serbian (sr)
Inventor
Chungen Liang
Kun Miao
Jianping Wang
Hongying Yun
Xiufang Zheng
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55910966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS59435(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of RS59435B1 publication Critical patent/RS59435B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RSP20191351 2015-05-08 2016-05-04 Nova jedinjenja sulfonimidoil purinona i njihovi derivati za lečenje i profilaksu virusne infekcije RS59435B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2015078507 2015-05-08
CN2016078785 2016-04-08
EP16720421.3A EP3294740B1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PCT/EP2016/059961 WO2016180695A1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number Publication Date
RS59435B1 true RS59435B1 (sr) 2019-11-29

Family

ID=55910966

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP20191351 RS59435B1 (sr) 2015-05-08 2016-05-04 Nova jedinjenja sulfonimidoil purinona i njihovi derivati za lečenje i profilaksu virusne infekcije

Country Status (32)

Country Link
US (3) US9708325B2 (enExample)
EP (1) EP3294740B1 (enExample)
JP (1) JP6738352B2 (enExample)
KR (1) KR102690131B1 (enExample)
CN (1) CN107580596B (enExample)
AR (1) AR104528A1 (enExample)
AU (3) AU2016260683B2 (enExample)
BR (1) BR112017023959B1 (enExample)
CA (1) CA2982704C (enExample)
CL (1) CL2017002745A1 (enExample)
CO (1) CO2017009994A2 (enExample)
CR (1) CR20170496A (enExample)
DK (1) DK3294740T3 (enExample)
ES (1) ES2753777T3 (enExample)
HR (1) HRP20191942T1 (enExample)
HU (1) HUE045906T2 (enExample)
IL (2) IL254947B (enExample)
LT (1) LT3294740T (enExample)
MX (2) MX393198B (enExample)
MY (1) MY182353A (enExample)
NZ (2) NZ735648A (enExample)
PE (1) PE20171620A1 (enExample)
PH (1) PH12017502009A1 (enExample)
PL (1) PL3294740T3 (enExample)
PT (1) PT3294740T (enExample)
RS (1) RS59435B1 (enExample)
RU (1) RU2745269C2 (enExample)
SG (1) SG10202108841YA (enExample)
SI (1) SI3294740T1 (enExample)
TW (2) TWI706954B (enExample)
UA (1) UA120450C2 (enExample)
WO (1) WO2016180695A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2982704C (en) * 2015-05-08 2023-10-24 F. Hoffmann-La Roche Ag Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PH12019500432B1 (en) * 2016-08-29 2023-03-24 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
MX388408B (es) * 2016-09-13 2025-03-19 Hoffmann La Roche Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ. ホフマン-ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
MA52412A (fr) * 2018-02-28 2021-06-02 Hoffmann La Roche Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
CN113660957B (zh) * 2019-02-12 2024-12-13 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
BR112022005137A2 (pt) 2019-09-20 2022-06-14 Syngenta Crop Protection Ag Derivados heterocíclicos com substituintes contendo enxofre e sulfoximina ativos em termos pesticidas
WO2021154664A1 (en) * 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097103A1 (en) * 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
EP4554678A1 (en) 2022-07-14 2025-05-21 F. Hoffmann-La Roche AG Phosphorylpurinone compounds for the treatment of cancer
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
CN101203519A (zh) * 2005-05-04 2008-06-18 辉瑞有限公司 用于治疗癌症和病毒感染如丙型肝炎的用作Toll样受体调节剂的2-酰氨基-6-氨基-8-氧代嘌呤衍生物
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
CN103497192B (zh) * 2008-12-09 2015-09-23 吉里德科学公司 Toll样受体调节剂
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
KR102025276B1 (ko) 2011-11-09 2019-09-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 치료를 위한 퓨린 유도체
AU2014242954B2 (en) 2013-03-29 2018-03-15 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
EA032824B1 (ru) 2014-08-15 2019-07-31 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
CA2982704C (en) * 2015-05-08 2023-10-24 F. Hoffmann-La Roche Ag Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PH12019500432B1 (en) * 2016-08-29 2023-03-24 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection

Also Published As

Publication number Publication date
AU2016260683A1 (en) 2017-10-12
KR20180003612A (ko) 2018-01-09
AR104528A1 (es) 2017-07-26
AU2016260683B2 (en) 2020-10-29
CO2017009994A2 (es) 2018-02-20
PE20171620A1 (es) 2017-11-02
SI3294740T1 (sl) 2019-12-31
US20170275286A1 (en) 2017-09-28
CR20170496A (es) 2017-12-05
IL280769A (en) 2021-04-29
MX376761B (es) 2025-03-07
TWI706954B (zh) 2020-10-11
EP3294740B1 (en) 2019-09-04
CL2017002745A1 (es) 2018-05-18
MX2020010949A (es) 2022-06-16
MY182353A (en) 2021-01-20
RU2017142577A (ru) 2019-06-10
PL3294740T3 (pl) 2020-03-31
MX393198B (es) 2025-03-19
JP6738352B2 (ja) 2020-08-12
EP3294740A1 (en) 2018-03-21
AU2020256348A1 (en) 2020-11-12
US20200109144A1 (en) 2020-04-09
AU2022204666A1 (en) 2022-07-21
CN107580596A (zh) 2018-01-12
ES2753777T3 (es) 2020-04-14
PH12017502009A1 (en) 2018-03-26
MX2017014033A (es) 2018-03-01
WO2016180695A1 (en) 2016-11-17
HRP20191942T1 (hr) 2020-01-10
JP2018515509A (ja) 2018-06-14
TWI768467B (zh) 2022-06-21
RU2017142577A3 (enExample) 2019-10-31
IL280769B2 (en) 2023-07-01
SG10202108841YA (en) 2021-09-29
BR112017023959A2 (pt) 2018-07-17
IL254947A0 (en) 2017-12-31
DK3294740T3 (da) 2019-11-04
HUE045906T2 (hu) 2020-01-28
HK1247925A1 (zh) 2018-10-05
BR112017023959B1 (pt) 2023-05-02
CN107580596B (zh) 2020-07-14
KR102690131B1 (ko) 2024-07-31
RU2745269C2 (ru) 2021-03-22
TW202108584A (zh) 2021-03-01
US10399983B2 (en) 2019-09-03
NZ775222A (en) 2024-09-27
CA2982704A1 (en) 2016-11-17
US20160326177A1 (en) 2016-11-10
US9708325B2 (en) 2017-07-18
AU2020256348B2 (en) 2022-06-16
LT3294740T (lt) 2019-11-25
US11242345B2 (en) 2022-02-08
CA2982704C (en) 2023-10-24
IL280769B1 (en) 2023-03-01
IL254947B (en) 2021-02-28
NZ735648A (en) 2023-06-30
TW201716410A (zh) 2017-05-16
PT3294740T (pt) 2019-10-29
UA120450C2 (uk) 2019-12-10

Similar Documents

Publication Publication Date Title
US11242345B2 (en) Sulfonimidoylpurinone compounds and methods of treatment using the same
JP7654643B2 (ja) ホスホジエステラーゼ阻害剤および使用
KR102030305B1 (ko) 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물
RU2380101C2 (ru) Бициклические пиримидины, ингибирующие hcv
RU2540332C2 (ru) Бициклические азотсодержащие гетероциклические соединения, полезные при лечении гепатита с
AU2006315334B2 (en) Aminopyrimidines useful as kinase inhibitors
JP7749602B2 (ja) アミドピリミドン誘導体
BRPI0619704A2 (pt) composto, composição, método para inibir a atividade da proteìna aurora quinase numa amostra biológica, método para tratar um distúrbio proliferativo e método para tratar cáncer
KR20100116206A (ko) Hsp90 저해제로서의 옥심 유도체
AU2008240313A1 (en) Aminopyrimidines useful as kinase inhibitors
CN114450277A (zh) 用于治疗和预防乙型肝炎病毒感染的经取代的嘧啶
HK1247925B (zh) 用於治疗和预防病毒感染的新的磺亚氨酰基嘌呤酮化合物和衍生物
HK40067638A (en) Substituted pyrimidine for the treatment and prophylaxis of hepatitis b virus infection
CN117715911A (zh) 癌症治疗中的n6-腺苷-甲基转移酶抑制剂
EP4251622A1 (en) Aromatic bridged ring amide derivatives for the treatment and prophylaxis of hepatitis b virus infection